Funder: National Institutes of Health (NIH)

Due Dates: November 7, 2025 (Full application) | October 7, 2025 (Earliest submission date) | Letter of intent due 30 days prior to application due date

Funding Amounts: Up to $750,000 direct costs/year for up to 5 years; NIH anticipates funding 4–5 awards with $4.73M total in FY26.

Summary: Supports preclinical development of lead candidate vaccines to prevent Mycobacterium tuberculosis (Mtb) infection and/or tuberculosis, expanding the clinical pipeline of viable vaccine candidates.

Key Information: Substantive industry participation is required for all applications; clinical trials are not allowed.